Skip to main content

Gubra

Gubra A/S is a Danish biotechnology company specialized in contract research services and peptide-based drug discovery for metabolic disorders. The company operates two main business segments, providing high-throughput preclinical contract research services alongside discovering proprietary target compounds in obesity and kidney disease. Main revenue drivers include fee-for-service preclinical research testing for external biopharmaceutical firms, milestone payments, and drug licensing partnerships. Gubra serves global pharmaceutical corporations, biotechnology developers, and academic research institutions across Europe, North America, and Asia. The company holds a specialized market position in preclinical metabolic disease research and automated peptide discovery. Headquartered in Horsholm, Denmark, Gubra A/S is listed on Nasdaq Copenhagen.

8 of the funds FundTelligence covers report a position in Gubra.

Sector
Health Care
Country
Denmark
Funds holding it
8
Exposure themes
Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health

Funds holding Gubra

Loading...